{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:26:49Z","timestamp":1793114809086,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s11060-023-04543-9","type":"journal-article","created":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T21:11:16Z","timestamp":1706994676000},"page":"431-440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery"],"prefix":"10.1007","volume":"166","author":[{"given":"Joseph D.","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew N.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyn","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammoren E.","family":"Dohm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil I.","family":"Khushalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Forsyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Vogelbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan J.","family":"Wuthrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiang-Hsuan M.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James K. C.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran A.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,3]]},"reference":[{"key":"4543_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/medsci9040063","author":"K Saginala","year":"2021","unstructured":"Saginala K, Barsouk A, Aluru JS, Rawla P, Barsouk A (2021) Epidemiology of melanoma. Med Sci (Basel). https:\/\/doi.org\/10.3390\/medsci9040063","journal-title":"Med Sci (Basel)."},{"key":"4543_CR2","unstructured":"National Cancer Institute (2023) SEER Cancer Stat Facts: Melanoma of the Skin. Accessed July 24. https:\/\/seer.cancer.gov\/statfacts\/html\/melan.html"},{"issue":"8","key":"4543_CR3","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/cncr.25634","volume":"117","author":"MA Davies","year":"2011","unstructured":"Davies MA, Liu P, McIntyre S et al (2011) Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117(8):1687\u20131696. https:\/\/doi.org\/10.1002\/cncr.25634","journal-title":"Cancer"},{"issue":"3","key":"4543_CR4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1177\/107327480901600307","volume":"16","author":"AE Sloan","year":"2009","unstructured":"Sloan AE, Nock CJ, Einstein DB (2009) Diagnosis and treatment of melanoma brain metastasis: a literature review. Cancer Control 16(3):248\u2013255. https:\/\/doi.org\/10.1177\/107327480901600307","journal-title":"Cancer Control"},{"issue":"2","key":"4543_CR5","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s11060-015-1932-9","volume":"125","author":"JE Bates","year":"2015","unstructured":"Bates JE, Youn P, Usuki KY et al (2015) Brain metastasis from melanoma: the prognostic value of varying sites of extracranial disease. J Neurooncol 125(2):411\u2013418. https:\/\/doi.org\/10.1007\/s11060-015-1932-9","journal-title":"J Neurooncol"},{"issue":"11","key":"4543_CR6","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1200\/jco.2004.11.044","volume":"22","author":"SS Agarwala","year":"2004","unstructured":"Agarwala SS, Kirkwood JM, Gore M et al (2004) Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 22(11):2101\u20132107. https:\/\/doi.org\/10.1200\/jco.2004.11.044","journal-title":"J Clin Oncol"},{"issue":"1","key":"4543_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1748-717X-7-77","volume":"7","author":"AV Tallet","year":"2012","unstructured":"Tallet AV, Azria D, Barlesi F et al (2012) Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment. Radiat Oncol 7(1):77. https:\/\/doi.org\/10.1186\/1748-717X-7-77","journal-title":"Radiat Oncol"},{"key":"4543_CR8","unstructured":"Lotze M, Dallal R, Kirkwood J, Flickinger J (2000) Cutaneous Melanoma En: Devita VT, Hellman S, Rosenberg SA, editors. Cancer Principles and Practice of Oncology. Philadelphia: Lippincott-Raven"},{"issue":"12","key":"4543_CR9","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1002\/cncr.33459","volume":"127","author":"ED Bander","year":"2021","unstructured":"Bander ED, Yuan M, Carnevale JA et al (2021) Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies. Cancer 127(12):2062\u20132073. https:\/\/doi.org\/10.1002\/cncr.33459","journal-title":"Cancer"},{"issue":"1","key":"4543_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3171\/jns.1998.88.1.0011","volume":"88","author":"JH Sampson","year":"1998","unstructured":"Sampson JH, Carter JH Jr, Friedman AH, Seigler HF (1998) Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88(1):11\u201320. https:\/\/doi.org\/10.3171\/jns.1998.88.1.0011","journal-title":"J Neurosurg"},{"issue":"7","key":"4543_CR11","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/s1470-2045(17)30429-1","volume":"18","author":"MA Davies","year":"2017","unstructured":"Davies MA, Saiag P, Robert C et al (2017) Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 18(7):863\u2013873. https:\/\/doi.org\/10.1016\/s1470-2045(17)30429-1","journal-title":"Lancet Oncol"},{"issue":"5","key":"4543_CR12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/s1470-2045(12)70090-6","volume":"13","author":"K Margolin","year":"2012","unstructured":"Margolin K, Ernstoff MS, Hamid O et al (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13(5):459\u2013465. https:\/\/doi.org\/10.1016\/s1470-2045(12)70090-6","journal-title":"Lancet Oncol"},{"issue":"1","key":"4543_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1200\/jco.18.00204","volume":"37","author":"HM Kluger","year":"2019","unstructured":"Kluger HM, Chiang V, Mahajan A et al (2019) Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial. J Clin Oncol 37(1):52\u201360. https:\/\/doi.org\/10.1200\/jco.18.00204","journal-title":"J Clin Oncol"},{"issue":"21","key":"4543_CR14","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1002\/cncr.32375","volume":"125","author":"E Rulli","year":"2019","unstructured":"Rulli E, Legramandi L, Salvati L, Mandala M (2019) The impact of targeted therapies and immunotherapy in melanoma brain metastases: a systematic review and meta-analysis. Cancer 125(21):3776\u20133789. https:\/\/doi.org\/10.1002\/cncr.32375","journal-title":"Cancer"},{"issue":"12","key":"4543_CR15","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/s1470-2045(21)00545-3","volume":"22","author":"HA Tawbi","year":"2021","unstructured":"Tawbi HA, Forsyth PA, Hodi FS et al (2021) Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol 22(12):1692\u20131704. https:\/\/doi.org\/10.1016\/s1470-2045(21)00545-3","journal-title":"Lancet Oncol"},{"issue":"3","key":"4543_CR16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2478\/raon-2022-0032","volume":"56","author":"JF Thompson","year":"2022","unstructured":"Thompson JF, Williams GJ, Hong AM (2022) Radiation therapy for melanoma brain metastases: a systematic review. Radiol Oncol 56(3):267\u2013284. https:\/\/doi.org\/10.2478\/raon-2022-0032","journal-title":"Radiol Oncol"},{"issue":"4","key":"4543_CR17","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000497211","volume":"42","author":"G Galli","year":"2019","unstructured":"Galli G, Cavalieri S, Di Guardo L et al (2019) Combination of immunotherapy and brain radiotherapy in metastatic melanoma: a retrospective analysis. Oncol Res Treat 42(4):186\u2013194. https:\/\/doi.org\/10.1159\/000497211","journal-title":"Oncol Res Treat"},{"issue":"6","key":"4543_CR18","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/s1470-2045(15)70057-4","volume":"16","author":"NU Lin","year":"2015","unstructured":"Lin NU, Lee EQ, Aoyama H et al (2015) Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol 16(6):e270\u2013e278. https:\/\/doi.org\/10.1016\/s1470-2045(15)70057-4","journal-title":"Lancet Oncol"},{"issue":"5","key":"4543_CR19","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1200\/JCO.21.02314","volume":"40","author":"MA Vogelbaum","year":"2021","unstructured":"Vogelbaum MA, Brown PD, Messersmith H et al (2021) Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol 40(5):492\u2013516. https:\/\/doi.org\/10.1200\/JCO.21.02314","journal-title":"J Clin Oncol"},{"issue":"5","key":"4543_CR20","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","volume":"19","author":"GV Long","year":"2018","unstructured":"Long GV, Atkinson V, Lo S et al (2018) Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 19(5):672\u2013681. https:\/\/doi.org\/10.1016\/S1470-2045(18)30139-6","journal-title":"Lancet Oncol"},{"issue":"8","key":"4543_CR21","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi HA, Forsyth PA, Algazi A et al (2018) Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med 379(8):722\u2013730. https:\/\/doi.org\/10.1056\/NEJMoa1805453","journal-title":"N Engl J Med"},{"issue":"2","key":"4543_CR22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/153303460300200211","volume":"2","author":"WHS Clair","year":"2003","unstructured":"Clair WHS, Given CA (2003) Stereotactic radiosurgery associated neurotoxicity. Technol Cancer Res Treat 2(2):147\u2013151. https:\/\/doi.org\/10.1177\/153303460300200211","journal-title":"Technol Cancer Res Treat"},{"issue":"4","key":"4543_CR23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.prro.2022.02.003","volume":"12","author":"V Gondi","year":"2022","unstructured":"Gondi V, Bauman G, Bradfield L et al (2022) Radiation therapy for brain metastases: an ASTRO clinical practice guideline. Pract Radiat Oncol 12(4):265\u2013282. https:\/\/doi.org\/10.1016\/j.prro.2022.02.003","journal-title":"Pract Radiat Oncol"},{"issue":"5","key":"4543_CR24","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/coc.0000000000000199","volume":"40","author":"KR Patel","year":"2017","unstructured":"Patel KR, Shoukat S, Oliver DE et al (2017) Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases. Am J Clin Oncol 40(5):444\u2013450. https:\/\/doi.org\/10.1097\/coc.0000000000000199","journal-title":"Am J Clin Oncol"},{"issue":"11","key":"4543_CR25","doi-asserted-by":"publisher","first-page":"12318","DOI":"10.18632\/oncotarget.7131","volume":"7","author":"H Soliman","year":"2016","unstructured":"Soliman H, Das S, Larson DA, Sahgal A (2016) Stereotactic radiosurgery (SRS) in the modern management of patients with brain metastases. Oncotarget 7(11):12318\u201312330. https:\/\/doi.org\/10.18632\/oncotarget.7131","journal-title":"Oncotarget"},{"key":"4543_CR26","doi-asserted-by":"publisher","unstructured":"Kotecha R, Miller JA, Venur VA et al (2018) Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and\/or immune-based therapies on treatment outcome. J Neurosurg 129:50\u201359. https:\/\/doi.org\/10.3171\/2017.1.Jns162797","DOI":"10.3171\/2017.1.Jns162797"},{"key":"4543_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113287","author":"AE Dohm","year":"2023","unstructured":"Dohm AE, Nakashima JY, Kalagotla H et al (2023) Stereotactic radiosurgery and anti-PD-1 + CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF\/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases. Eur J Cancer. https:\/\/doi.org\/10.1016\/j.ejca.2023.113287","journal-title":"Eur J Cancer"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-023-04543-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-023-04543-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-023-04543-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T09:12:10Z","timestamp":1708333930000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-023-04543-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["4543"],"URL":"https:\/\/doi.org\/10.1007\/s11060-023-04543-9","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"26 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Joseph D. Tang: no disclosures. Matthew N. Mills: no disclosures.Justyn Nakashima: no disclosures.Ammoren E. Dohm: no disclosures.Nikhil I. Khushalani: personal consulting fees from Astra-Zeneca, Bristol Myers Squibb, Incyte, Iovance, Merck, Novartis, Nektar, Replimune, Regeneron, Jounce, Castle Biosciences, and Instill Bio; receives research funding from Bristol Myers Squibb, Merck, Novartis, Replimune, Celgene, Regeneron, HUYA Biopharmaceuticals, and GlaxoSmithKline; and has common stock holdings in Bellicum Pharmaceuticals, Amarin Corp, and Asensus Surgical. Peter A. Forsyth: has funding from Pfizer and Celgene and is on the advisory boards of Novocure, BTG, Inovio, AbbVie, Ziopharm, Tocagen, and Pfizer. Michael A. Vogelbaum: has indirect equity and royalty interests in Infuseon Therapeutics, Inc. and has received honoraria from Tocagen, Inc. and Celgene. Evan J. Wuthrick: has served on the advisory board and has received honoraria from Bayer, has received research funding from Bristol-Myers Squibb, and has intellectual property: cGMP as protector for chemotherapy and radiation. Hsiang-Hsuan Michael Yu: has received speaker\u2019s honoraria from BrainLab and is on the advisory boards of Novocure and AbbVie. Daniel E. Oliver: no disclosures. James K.C. Liu: no disclosures. Kamran A. Ahmed: has received research funding from Bristol-Myers Squibb, Eli Lilly, and Genentech.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}